Eli Lilly Agrees to Acquire Calytrix Bio for Up to $1.5 Billion
The drugmaker acquires the biotech firm's preclinical antibody assets for essential thrombocythemia and myelofibrosis.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The story so far
2 publishers have covered this in 4 articles since 16 Nov 2026. Bloomberg.com published first, on 16 November at 12:05 UTC; Quartz followed 1h 55m later. The most recent article, from Bloomberg Markets, appeared on 16 November at 17:25 UTC.
Outlets reporting it: Bloomberg Markets (major outlet), Quartz.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- Bloomberg.comEli Lilly Agrees to Buy Calytrix Bio for Up to $1.5 Billion
- QuartzEli Lilly kauft ein Biotech-Unternehmen für seltene Blutkrebserkrankungen für bis zu 1,5 Milliarden Dollar.
- QuartzEli Lilly is buying a rare blood cancer biotech for up to $1.5 billion
- Bloomberg MarketsLilly Pushes Buying Spree Beyond $32B With Calytrix Deal
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Lilly Pushes Buying Spree Beyond $32B With Calytrix Deal Bloomberg Markets ·
- Eli Lilly Agrees to Buy Calytrix Bio for Up to $1.5 Billion Bloomberg.com ·
- Eli Lilly kauft ein Biotech-Unternehmen für seltene Blutkrebserkrankungen für bis zu 1,5 Milliarden Dollar. Quartz
- Eli Lilly is buying a rare blood cancer biotech for up to $1.5 billion Quartz
In this story
- Eli Lilly & Co.
- Calytrix Bio Inc.